Sinopharm Group Co. Ltd. (Stock Code: 01099) released its unaudited financial information for the nine months ended 30 September 2025, prepared under PRC GAAP. According to the consolidated statements, the Group reported total assets of approximately RMB418.38 billion, up from RMB392.67 billion as of 31 December 2024. Total liabilities stood at around RMB286.21 billion, while owners’ equity reached about RMB132.17 billion.

Operating revenue for the period was approximately RMB431.48 billion, with operating cost at RMB400.21 billion. The Group’s net profit was approximately RMB8.10 billion, of which RMB5.31 billion was attributable to equity holders of the parent. Basic earnings per share stood at RMB1.70.

In the Company’s standalone statements, total assets were approximately RMB76.93 billion and total liabilities amounted to RMB44.54 billion as of 30 September 2025. The Company recorded operating revenue of about RMB15.54 billion and net profit of approximately RMB1.21 billion for the nine-month period.

The board of directors stated that these financial statements fulfill the Company’s disclosure obligations under relevant regulations and reflect the Group’s performance up to 30 September 2025.